Member Info for flava

My 4k top-up at 33p not showing.

Let them enjoy the 10% profits. 😄 The real money is made by taking a position before the JV/takeover deal.

MM's ask 2 x 36p , 2 x 38p and then 39p /40p

The 40p resistance has been broken twice now. We need the third attempt to be successful and sustain that momentum to reach 60p.

40p need to hold first then 60p.

58p may need to be retested at some point to break out. GLA

It appears that RUA Structural Heart has shifted its strategic focus from developing its own heart valve to licensing its composite material to other companies in the heart valve industry. This approach will allow RUA to capitalise on the commercial potential of its composite material more quickly and efficiently than developing its own valve.

By providing its composite material to other companies, RUA can benefit from the expertise and resources of these companies in developing and commercialising new heart valves. Additionally, RUA can avoid the risks and costs associated with developing and manufacturing its own valve.

The company's decision to broaden its licensing efforts further suggests that it is confident in the potential of its composite material. By providing the material to a wider range of companies, RUA can increase the chances that its material will be used in new and innovative heart valves. This could lead to significant revenue and market share for RUA.

Overall, RUA's strategic shift to licensing its composite material appears to be a sound one that could position the company for long-term success in the heart valve industry.

Edwards and Medtronic could be our JV or takeover company.

RUA Life Sciences group current Mcap under £8.5 million 👈

If RUA captures just 1% of the heart valve market = $200 million 👈

5% market share = $1 billion

The number of sellers appears to be dwindling. 58p may need to be retested at some point to break out. GLA

The facts are readily available in the company's official publications.

RUA Life Sciences group current Mcap under £8.5 million 👈

If RUA captures just 1% of the heart valve market = $200 million 👈

5% market share = $1 billion

Those are the facts and investors should be aware that RUA hydrodynamic testing demonstrated valve efficiency around 50% better than current technology. 👈👈👈

and valve flow area is around 25% larger than similar sized valves in the market. 👈👈

We have a far superior product coming, and the two Edwards and Medtronic big players will be eager to get their hands on it.

Like yesterday, the price dropped to 10% and then rebounded to 20%. Hopefully, this time the rebound will be stronger.

We all know someone who will manipulate others for their own benefit. I would just ignore the sad trolls who have nothing better to do with their time.

The fact is that the numbers don't lie - RUA Market cap is too low for what they have in the pipeline.

RUA Life Sciences group current Mcap under £8.5 million 👈

If RUA captures just 1% of the heart valve market = $200 million 👈

5% market share = $1 billion

Just hold your golden tickets. some pi's panicked sold yesterday!

I can see that shorters are posting scary Santa Claus content to panic new investors here.

Just ignore the noise and focus on your investments. GLA!

RUA Life Sciences group current Mcap under £8.5 million 👈

If RUA captures just 1% of the heart valve market = $200 million 👈

5% market share = $1 billion

Those are the facts and investors should be aware that RUA hydrodynamic testing demonstrated valve efficiency around 50% better than current technology. 👈👈👈

and valve flow area is around 25% larger than similar sized valves in the market. 👈👈

We have a far superior product coming, and the two Edwards and Medtronic big players will be eager to get their hands on it.

Take over or JV deal with major players facts:

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves

Edwards Lifesciences Market cap 40 billion 👈 https://www.edwards.com/

Edwards heart valve cost? The new valves currently sell for up to $30,000 👈

How big is the heart valve market?

Heart Valve Devices Market Outlook (2022-2032) The global heart valve devices market is likely to be valued at US$ 11.16 Billion in FY 2022, up from US$ 9.85 Billion in 2021. During the past year, the industry registered a Y-o-Y increase worth 13.3%.

The global heart valve market is projected to reach $19.7 billion by 2031, growing at a CAGR of 11.1% from 2022 to 2031.

RUA Structural Heart

Structural Heart is exceeding management's expectations with regards to the development and testing of the Company's novel composite material for the creation of heart valve leaflets. The composite which benefits from Elast-Eon's biostability and blood contacting properties is designed to improve the durability of flexible leaflet heart valves. Recent testing results have surpassed key milestones.

· flex fatigue testing for durability passed 400 million cycles equivalent to 10 years in man.👈

· a heart valve made of the composite has achieved the key 200 million cycles required by ISO standards for a flexible leaflet heart valve. 👈

· hydrodynamic testing demonstrated valve efficiency around 50% better than current technology. 👈👈👈

· valve flow area is around 25% larger than similar sized valves in the market. 👈👈

· Recent patent filing to protect the new IP entitled "Composite Material, Heart Valve and Method of Manufacture".

Excellent post, IntraVnus 👏

For me, after reading the latest RNS, someone mentioned before here that a Take Over or joint venture deal is on the card next.

Edwards and Medtronic are likely to be watching RUA's progress with great interest. Both companies have a strong track record of innovation in the heart valve market, and they are not likely to cede their leadership position without a fight. However, RUA's disruptive technology could pose a serious threat to their dominance. If RUA is able to successfully commercialise its heart valve, it could capture a significant share of the market and force Edwards and Medtronic to adapt.

💰💰 The heart valve market is worth an estimated $10 billion annually. 💰💰

Don't forget that the SP dropped in December 2021 from 165p due to the FDA requiring additional data to facilitate the 510k approval.

July 2023 - RUA Vascular and the FDA reached an agreement on the regulatory pathway for the company's polymerically sealed vascular grafts. This agreement is expected to expedite the approval process for the grafts. Additionally, RUA Vascular also signed a global distribution agreement in July 2023, which will provide the company with access to a global market for its products.

November 2023 - RUA Vascular has now reached the stage of being fully prepared to commence the regulatory testing regime agreed with the FDA through the pre-submission process to achieve 510k approval.

These two developments are significant milestones for RUA Vascular and bring the company closer to commercialising its innovative vascular grafts.

We're now back to normal and 150p is still cheap.

That's because you couldn't buy 20k in one go and had to split it into 8k, 9k, or 10k chunks. If you add up the total buys over £55k at 54p+ in the space of one hour yesterday alone.

Abouelatly bargain price to buy now. Large buyers paid 58.40p yesterday.

https://prnt.sc/PNkZqKG2mxrN

PIs chasing rainbows will be paying a higher price later. Get in here now.

I have added more now and I am happy to wait for 150p.